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Polybrominated diphenyl ethers (PBDEs) are 
a class of flame-retardant chemicals frequently 
applied to textiles, furniture, and electronic and 
electrical items. Large amounts of PBDEs have 
been produced and applied over the past few 
decades, resulting in widespread contamination 
of the environment and accumulation in food 
webs. Furthermore, because of their physico-
chemical properties, PBDEs are persistent in the 
environment and bioaccumulate in both aquatic 
and terrestrial food webs (Alaee et al. 2003; 
Christensen et al. 2005; de Wit et al. 2006; Law 
et al. 2006).
A number of laboratory animal exposure 
studies have found significant species-specific 
differences in uptake kinetics, metabolism, and 
disposition of several different 14C-labeled and 
unlabeled PBDE congeners. For example, mice 
or rats exposed in vivo to 2,2´,4,4´,5-penta-
bromodiphenyl ether (BDE-99) have been 
found to produce oxidative metabolites, such 
as hydroxylated BDE congeners (OH-BDE) 
(Chen et al. 2006; Hakk et al. 2002; Qiu et al. 
2007). However, in vivo exposure of common 
carp (Cyprinus carpio) to BDE-99 resulted 
in significant formation and accumulation 
of a reductively debrominated metabolite, 
2,2´,4,4´-tetrabromodiphenyl ether (BDE-47) 
(Stapleton et al. 2004). In addition, the extent 
of metabolism in these studies depends on the 
structure and bromine substitution of the BDE 
congener. BDE-99 appears to be metabo-
lized to a greater extent than does BDE-47, 
2,2´,4,4´,5,5´-hexabromodiphneyl ether 
(BDE-153), or 2,2´,3,3´,4,4´,5,5´,6,6´-deca-
bromodiphenyl ether (BDE-209) (Chen et al. 
2006; Morck et al. 2003; Staskal et al. 2006). 
Thus, these laboratory PBDE metabolism 
studies suggest that humans will accumulate 
and metabolize PBDEs; however, it is not clear 
how PBDEs are specifically metabolized in 
human tissues and what types of metabolites 
will be formed.
Studies have documented measurements 
of PBDEs in several different human popula-
tions, and their presence in tissues appears 
to be ubiquitous (Hites 2004; Schecter et al. 
2003; Sjodin et al. 2001). The primary con-
geners detected in human tissues include 
BDE congeners 47, 99, and 153, which are 
the primary congeners found in a commer-
cial mixture referred to as pentaBDE. To our 
knowledge, no studies have investigated the 
metabolism of BDE congeners in human tis-
sues. Analyses of human sera have identified 
multiple OH-BDE congeners, suggesting that 
metabolism does occur (Athanasiadou et al. 
2008); however, natural sources of OH-BDEs 
have also been identified in marine environ-
ments (Malmvarn et al. 2005). The forma-
tion of OH-BDE metabolites is of concern 
because greater adverse effects have been doc-
umented for the OH-BDEs relative to the 
PBDEs in laboratory studies. For example, 
OH-BDEs have been shown to significantly 
affect aromatase activity in human adreno-
cortical carcinoma cells, whereas PBDEs had 
no effect (Canton et al. 2005). In addition, 
OH-BDEs have an order of magnitude higher 
potency than do PBDEs in their ability to 
compete with thyroid hormones for binding 
sites on serum transporters (Hamers et al. 
2006; Meerts et al. 2000, 2001).
We undertook the present study to deter-
mine whether PBDE metabolites could be 
detected after in vitro exposure to human 
hepatocytes. Our objective was to determine if 
reductively debrominated and/or OH metabo-
lites of BDE congeners 99 and 209 (i.e., the 
primary congeners found in the penta  BDE 
and decaBDE commercial mixtures) would 
be produced by human hepato  cytes. We also 
designed this study to examine the expression 
of genes coding for the enzymes potentially 
involved in the metabolism of PBDEs through 
oxidative and reductive pathways.
Materials and Methods
Chemicals and materials. The test compounds, 
BDE-99 (100 ± 4% purity) and BDE-209 
(deca  bromo  diphenyl ether, 98 ± 1% purity), 
were obtained from AccuStandard, Inc. 
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Ba c k g r o u n d: Polybrominated diphenyl ethers (PBDEs) are flame-retardant chemicals that 
  accumulate in human tissues and are potential toxicants. Concentrations of PBDEs in human tis-
sues have increased recently, and body burdens in the U.S. and Canadian populations are higher 
than in any other region.
oBjectives: Although metabolism in animal laboratory studies has been examined, no studies have 
explored the metabolism of these contaminants in human tissues. We undertook this study to deter-
mine whether PBDEs could be metabolized by human liver cells in vitro and to identify what types 
of metabolites are formed.
Me t h o d s : We exposed hepatocytes from three different donors (two cryopreserved batches and one 
fresh batch) to solutions containing 10 µM of either of two environmentally relevant and prominent 
PBDE congeners—BDE-99 or BDE-209—for periods of 24–72 hr. We also conducted gene expres-
sion analysis to provide information on potential induction of xenobiotic metabolizing enzymes.
re s u l t s: Exposing hepatocytes to BDE-99 resulted in the formation of 2,4,5-tribromo  phenol, two 
monohydroxylated pentabrominated diphenyl ether metabolites, and a yet unidentified tetra  brominated 
metabolite. No hydroxylated or debrominated metabolites were observed in the cells exposed to 
BDE-209. This suggests that BDE-209 was not metabolized, that non  extractable, covalently protein-
bound metabolites were formed, or that the exposure time was not long enough for BDE-209 to diffuse 
into the cell to be metabolized. However, we observed up-regulation of genes encoding for cytochrome 
P450 monooxygenase (CYP) 1A2, CYP3A4, deiodinase type 1, and glutathione S-transferase M1 in 
hepatocyes exposed to both BDE-99 and BDE-209.
co n c l u s i o n s: Our in vitro results suggest that the human liver will likely metabolize some BDE 
congeners (e.g., BDE-99) in vivo. These metabolites have been shown to elicit greater toxicity than 
the parent BDE congeners in laboratory bioassays; thus, more research on body burdens and human 
health effects from these metabolites are warranted.
key w o r d s : brominated flame retardants, hepatocytes, metabolism, OH-PBDEs, polybrominated 
diphenyl ethers. Environ Health Perspect 117:197–202 (2009).  doi:10.1289/ehp.11807 available 
via http://dx.doi.org/ [Online 2 September 2008]Stapleton et al.
198  v o l u m e  117 | n u m b e r 2 | February 2009  •  Environmental Health Perspectives
(New Haven, CT, USA) and Sigma (St. 
Louis, MO, USA), respectively. We also 
obtained 2,4,6-tribromo  phenol (99% purity) 
and rifampicin (95% purity) from Sigma. 
We purchased mono  fluorinated PBDEs 
[4´-fluoro-2,3´,4,6-tetrabromodiphenyl ether 
(F-BDE-69; 98.2% purity) and 4-fluoro-
2,3,3´,4,5,6-hexabromodiphenyl ether 
(F-BDE-160; 98.1% purity)], used as inter-
nal and surrogate standards, from Chiron 
(Trondheim, Norway) and 13C-labeled 
BDE-209 (decabromodiphenyl ether; 
> 98% purity), 13C-labeled 6-OH-BDE-47 
(6-OH-2,2´,4,4´-tetrabromodiphenyl 
ether), and a mixture of eight methoxylated 
PBDEs (MeO-PBDEs; > 98% purity) from 
Wellington Laboratories (Guelph, Ontario, 
Canada). All solvents and other reagents 
used in these experiments were of analytical 
grade or higher. For all experiments, we used 
In Vitro Technologies (Celsis Inc., Baltimore, 
MD, USA) hepatocytes, culture medium, 
anti  biotics, and collagen-coated culture plates.
Hepatocyte incubations. We used cultured 
hepatocytes from three individual donors: 
two cryopreserved (one male and one female) 
and one (male) “fresh” (shipped within 48 hr 
of the donor’s passing). Donor information, 
including sex, age, race, body mass index, 
alcohol use, tobacco use, drug use, medical 
history, medication use, cause of death, and 
measured metabolic activities (provided by 
supplier), are listed in Table 1.
Cryopreserved human hepatocytes arrived 
in 1-mL vials at –80°C in liquid nitrogen. 
Before thawing, we added 5.5 mL Torpedo 
Antibiotic Mix to 250 mL InVitroGRO CP 
Media and warmed the mixture to 37°C. We 
immersed frozen vials of hepatocytes in a 37°C 
water bath, gently shook them until thawed, 
and then added them to 5 mL of the medium–
antibiotic mix. We determined cell viability by 
the trypan blue exclusion method. The initial 
viability of the cryopreserved hepato  cytes after 
thawing was high (> 83%), and we plated cells 
in a 12-well plate at a density of 7.0 × 105 
cells/mL. We incubated the cultures undis-
turbed for 24 hr to allow for cell adhesion. 
Afterward, we visually inspected confluence 
under a microscope (10×) and exchanged the 
plating media for experimental dosing media. 
Fresh hepatocytes were seeded by the 
manufacturer (Celsis Inc., Baltimore, MD, 
USA) at a seeding density of 160,000 cells/
cm2 and were shipped overnight at 4°C, pre-
plated on a 12-well plate with the cell cultures 
immersed in a proprietary “shipping medium.” 
Upon arrival, we placed the hepato  cytes in 
the incubator for 3 hr to equilibrate and then 
exchanged the shipping medium for experi-
mental dosing media. Table 1 summarizes the 
conditions of the plated cell cultures, including 
initial cell viability, viable cell density on plates, 
and confluence before experimental dosing.
We used InVitroGRO HI Media (Celsis 
Inc.) with Torpedo Antibiotic Mix for dos-
ing the hepatocytes and for maintaining the 
cell cultures for the remaining experiments. 
BDE-99, BDE-209, and rifampicin solutions 
were prepared in dimethyl sulfoxide (DMSO) 
at a concentration 100 times that of the 
desired final concentration in order to mini-
mize hepatocyte exposure to the dosing vehi-
cle. DMSO dosing solution was then diluted 
1:100 in InVitroGRO HI Media to yield final 
concentrations of 10 µM for BDE-99 and 
BDE-209 and 2.5 µM for rifampicin. We con-
ducted experimental dosing of the hepatocytes 
using three to four replicates (wells) per treat-
ment. Wells were treated with media contain-
ing BDE-99, BDE-209, or clean media only 
(control). All three hepatocyte batches were 
exposed to BDE-99 and BDE-209 at a nomi-
nal concentration of 10 µM, equivalent to 
10 nmol of each compound per well. Aliquots 
of the BDE dosing media were also incubated 
(in triplicate) alone on the well plates adjacent 
to the hepatocytes as controls and analyzed at 
the end of exposure to determine the expo-
sure concentrations. Separate 12-well plates 
were used for the metabolism and gene expres-
sion analysis. We conducted gene expression 
analysis using only fresh hepatocytes because 
of insufficient recovery of RNA in the cryo-
preserved hepatocytes.
We conducted steps involving manipu-
lation of cell cultures in a biological safety 
cabinet under sterile conditions. Plated cell 
cultures were maintained in a saturating 
humidity incubator at 37°C and 5% CO2 dur-
ing incubations. Cryopreserved cell cultures 
were allowed to incubate with one dose of 
experimental media for 48 hr. Plates of fresh 
hepatocyte cultures used for the metabolism 
studies were treated once every 24 hr for 3 days 
to take advantage of the increased activity of 
fresh cells and potential increase in metabolite 
formation. During medium exchange in the 
fresh hepatocytes, we collected and pooled 
the contents from each well. Fresh hepatocyte 
cultures used for the gene expression analysis 
were allowed to incubate with one dose of the 
experimental media for 24 hr. After incuba-
tion, the hepatocytes were removed from the 
wells using 1 mL methanol (only wells used 
in the metabolism study) to disrupt cell mem-
branes. The contents were subsequently trans-
ferred to clean glass test tubes for extraction.
Sample extraction. Hepatocytes and media 
were extracted using methods developed for 
the extraction of phenolic and neutral com-
pounds from serum (Hovander et al. 2000). 
Briefly, samples were first spiked with three 
internal standards—F-BDE-160, 13C-labeled 
6-OH-BDE-47, and 13C-labeled BDE-
209—and extracted using methyl-tert-butyl 
ether:hexane (1:1). Lipids were removed from 
the extracts with concentrated sulfuric acid, 
and then the neutral and phenolic compounds 
were separated using a basic aqueous solution 
of potassium hydroxide. The phenolic fraction 
was derivatized with an ethereal solution of 
diazo  methane to produce MeO metabolites 
for GC/MS analysis.
Sample analysis. We analyzed all samples 
using gas chromatography–mass spectrometry 
(GC/MS) operated in both electron-impact 
mode (GC/EI-MS) and electron-capture 
negative-ionization mode (GC/ECNI-MS). 
The GC/MS operating conditions have been 
described previously (Stapleton et al. 2008). 
We confirmed metabolites in both GC/EI-MS 
Table 1. Hepatocyte donor characteristics.
  Donor
Characteristic  1  2  3
State of shipped hepatocyes  Cryopreserved   Fresh   Cryopreserved 
Lot no.  KQG  MHU-L-092507  ONQ
Experimental repetitions (n)  2  1  1
Sex  Female  Male  Male
Age (years)  38  50  61
Race  Caucasian  Caucasian  Caucasian
Body mass index  38.6  34.4  42.9
History of alcohol use  Yes  Yes  Yes
History of narcotic use  None reported  None reported  None reported
History of tobacco use  Yes  None reported  Yes
Relevant medical history  None reported  None reported  None reported
Relevant chronic medications  None reported  None reported  None reported
Cause of death  Cerebrovascular accident (stroke)  Head trauma  Head trauma
Initial viability (%)  83.8  93a  83.7
Viable cell density (cells/mL)  7.0 × 105  NA  7.0 × 105
Confluence at 24 hr (%)  80  70  50–60
Metabolic activityb (pmol/106 cells/min)
  Formation of 7-hydroxycoumarin  49  N/A  66
  Formation of 7-hydroxycoumarin glucuronide  191  NA  247
  Formation of 7-hydroxycoumarin sulfate  12  NA  47
  Formation of 6β-hydroxytestosterone  108  NA  60
  Formation of 4´-methylhydroxytolbutamide  25  NA  18
NA, not available.
aAt time of plating (measured by supplier). bProvided by hepatocyte supplier.Metabolism of PBDEs by human hepatocytes
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 2 | February 2009  199
and GC/ECNI-MS modes. We moni  tored 
PBDEs, MeO-BDEs, and the fluorinated 
BDEs using the m/z responses of 79 and 81 
(bromide ions), and BDE-209 and 13C-BDE-
209 using m/z responses of 486.6, 484.6, 
496.6, and 494.6 in GC/ECNI-MS mode. 
We analyzed OH-BDE metabolites by GC/
ECNI-MS using responses of MeO-BDE 
calibration standards. The National Wildlife 
Research Centre provided further analysis of 
phenolic fractions for possible BDE-209 oxida-
tive metabolites using an Alliance 2695 high-
performance liquid chromatograph (Waters 
Corporation, Milford, MA, USA) connected 
to a Waters Quattro Ultima triple quadru-
pole mass spectrometer (LC/MS-MS). Because 
OH-nona-BDE congeners are not commer-
cially available, we optimized all methods using 
the LC/MS-MS using 6-OH-BDE-90.
Gene expression analysis. We collected 
RNA only from the fresh hepatocytes after 
24 hr of exposure to the dosing media. We 
did not examine gene expression in the cryo-
preserved hepatocytes because of low recov-
ery of RNA. The analysis was conducted to 
determine the expression of several genes that 
encode potential biotransforming enzymes, 
including cytochrome P450 mono  oxygenase 
(CYP) 1A2, CYP3A4, deiodinase (DI) types 1 
and 2, glutathione S-transferase (GST) M1, 
and GSTP1. Absolute transcript numbers 
were quantified using a Stratagene Mx3000P 
Real Time PCR (polymerase chain reac-
tion) apparatus (Stratagene, La Jolla, CA). 
We developed protocols using SYBR Green I 
(Molecular Probes, Inc., Eugene, OR, USA). 
Because SYBR Green I can bind nonspecifi-
cally to all double-stranded DNA, optimiza-
tion steps were performed to eliminate signals 
obtained from either primer-dimer complexes 
or other nonspecific products. We monitored 
the expression of CYP1A2 [GenBank acces-
sion no. NM_000761 (National Center for 
Biotechnology Information 2008)], CYP3A4 
(NM_017460), DI1 (NM_000792), GSTM1 
(NM_000561), and GSTP1 (NM_000852) 
using published primer sequences (Brasch-
Andersen et al. 2004; Chanas et al. 2002; 
Lindell et al. 2003; Yamaori et al. 2005). We 
used glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as a housekeeping gene control 
for data analysis following published protocols 
(Strehlau et al. 1997). Each reaction was per-
formed in a 25-µL reaction mixture consisting 
of 12.5 µL 2× iTaq SYBR Green Supermix 
with ROX (Stratagene, Hercules, CA, USA), 
0.2 µM reverse and forward primers, 1 µL 
template, and 9.5 µL deionized water. The 
thermal cycler program consisted of an ini-
tial denaturing step at 95°C for 3 min, fol-
lowed by 40 cycles of 95°C for 30 sec, 62°C 
for CYP3A4 (56°C for CYP1A2, 62°C for 
DI1, 60°C for GSTM1, 57°C for GSTP1, and 
62°C for GAPDH) for 30 sec, and 72°C for 
30 sec. The absolute target transcript number 
was calculated based on a standard curve pre-
pared as described previously (Pei et al. 2006). 
Statistical significance was determined by per-
forming a paired Student’s t-test comparing 
transcript numbers between the negative con-
trol (no BDE) and each treatment.
QA/QC and data analysis. Recovery of 
surrogate standards F-BDE-69, 13C-6-OH-
BDE-47, and 13C-BDE-209 averaged 86 ± 
12%, 50 ± 7%, and 47 ± 44%, respectively. 
Analyte values were corrected for recovery. 
Laboratory blanks did contain minor amounts 
of BDE-99 (< 3 ng); however, given the high 
concentrations used in the dosing, blank cor-
rection was not necessary. Levels of all metabo-
lites observed were below limits of detection 
(LODs) in all laboratory blanks and hepatocyte 
control samples. We defined LODs as three 
times the SD of the laboratory blanks. For con-
geners not detected in the blanks, we set the 
LOD at the instrumental limit of quantifica-
tion. BDE, metabolite, and gene expression 
data were analyzed for statistical significance by 
performing paired Student’s t-tests. For gene 
expression, we compared transcript numbers 
between the negative control (no BDE) and 
each treatment. All statistical analyses were 
carried out using Microsoft Excel (Microsoft 
Corp., Redmond, WA, USA), with the statisti-
cal significance defined at α = 0.05.
Results and Discussion
Table 1 presents descriptive information 
regarding donor characteristics, handling of 
hepatocytes, and viability of cells. All experi-
ments showed optimal confluence (i.e., > 70%) 
except one, which displayed a confluence of 
about 50–60%. We observed no apparent dif-
ferences in cytotoxicity between exposed and 
control hepatocytes based on visual inspec-
tion under the microscope. This is consistent 
with a previously published study using human 
adreno  cortical carcinoma cells exposed to a 
similar concentration of BDE-99 in which no 
cytotoxicity was measured with a mitochon-
drial toxicity test (Canton et al. 2006).
BDE dosing and recovery. The mass 
of BDE-99 and BDE-209 to which the 
cells were exposed was 10.47 ± 0.50 and 
8.72 ± 0.25 nmol/well, respectively, using 
GC/ECNI-MS. We meas  ured concentrations 
of BDEs in the neutral fractions of extracts col-
lected from the hepatocytes. Because the fresh 
hepatocytes were repeatedly exposed (exposure 
media replenished once daily for 3 days), we 
performed a mass balance only on the cryo-
preserved hepatocytes that were dosed once. 
After the 48-hr incubation, we recovered 9.62 
± 0.11 and 8.28 ± 0.16 nmol BDE-99 and 
BDE-209, respectively, in the cryopreserved 
hepatocyte wells. Therefore, it appears that 
approximately 8% of the BDE-99 mass was 
unrecovered, but only 3% of BDE-209 mass. 
The greater amount of unrecovered mass of 
BDE-99 is likely attributed to metabolism, 
since we observed metabolites of BDE-99. 
Most of the BDE-209 mass was recovered, 
which suggests that little to no metabolism 
occurred. We could not estimate the frac-
tion of BDE mass that actually diffused into 
the cells and was available for metabo  lism. 
It is possible that diffusion of BDE-209 into 
hepato  cytes is a slow process and that we did 
not provide adequate time to observe induc-
tion of enzymes (e.g., CYPs) and subsequent 
metabolism. We did not perform additional 
experiments with various dosing levels of 
BDEs and different exposure periods; our pri-
mary focus was to determine if metabolism was 
consistent among hepatocytes harvested from 
three different individuals, providing insight 
into expected metabolic capability among the 
general population. Furthermore, the high 
dose we used in this study increased the likeli-
hood of detecting metabolites. The exposure 
used in this study (~ 10 µM) is rela  tively high 
and not environmentally rele  vant for human 
exposure. Concentrations of total BDEs in 
human blood and milk typically average about 
≤ 0.5 nM (Schecter et al. 2003, 2005; Sjodin 
et al. 2004), yet BDE levels measured in adi-
pose tissue are higher, with a mean value of 
132 nmol/kg adipose tissue being reported for 
BDE-99 (Johnson-Restrepo et al. 2005).
Metabolite identification. We observed 
no reductively debrominated metabolites in 
the neutral extracts isolated from the hepato-
cytes exposed to either BDE-99 or BDE-209, 
indicating that the metabolic reductive debro-
mination does not occur or that the expo-
sure period of this assay was too small. This 
suggests that reductive debromination is not 
likely to be a substantial metabolic pathway 
in human liver tissue. These results are in con-
trast to several in vivo studies and one in vitro 
study using liver subcellular fractions that 
showed significant reductive debromination 
of BDE congeners 99, 183, and 209 in fish, 
rodents, and birds (Huwe and Smith 2007; 
Kierkegaard et al. 1999; Stapleton et al. 2004; 
Tomy et al. 2004; Van den Steen et al. 2007).
To determine whether oxidative metabo-
lites were being formed during our experi-
ment, we isolated the phenolic fraction of the 
extract, which we then derivatized to methyl 
analogs and analyzed using GC/ECNI-MS. 
Extracts from the phenolic fraction of hepato-
cytes exposed to BDE-209 revealed no oxida-
tive metabolites. We hypothesized that steric 
hindrance from the large number of bromine 
atoms substantially decreases the degree of 
derivatization of any potential nona-OH-BDE 
metabolites to their MeO analogs. To exam-
ine this possibility, we analyzed the phenolic 
fractions using LC/MS-MS (see “Materials 
and Methods”). LC/MS-MS analyses of these 
fractions for the [M+→Br–] multiple reaction Stapleton et al.
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monitoring transition of OH derivatives of 
penta-, hexa-, hepta-, octa-, and nona-BDE 
analytes were all below LOD (< 0.05 ng/mL). 
Thus, no specific metabolites of BDE-209 
were identified in this study. It is possible that 
metabolism led to reactive intermediates (e.g., 
arene oxides) that covalently bound BDE-209 
to cellular lipids and/or proteins, which are 
not recovered during the extraction process. 
This has indeed been observed in rodent expo-
sure studies using radio  labeled BDEs (Hakk 
et al. 2002; Morck et al. 2003). Further stud-
ies using radio  labeled BDE-209 are needed to 
determine if metabolism leading to covalent 
binding is occurring in human hepatocytes.
In contrast to the BDE-209 exposure, 
we observed several oxidative metabolites in 
all hepatocytes exposed to BDE-99. As shown 
in Figure 1, four metabolites were identified. 
Because a liquid/liquid extraction technique was 
used to separate the neutral and phenolic frac-
tions, a small proportion of BDE-99 was identi-
fied in the phenolic fraction; however, the mass 
of BDE-99 in the phenolic fraction accounted 
for < 0.09% of the initial dose. Metabolite 1 
has been identified as a tribromo  phenol and 
is likely 2,4,5-tribromo  phenol. Figure 2 pres-
ents the GC/EI-MS and GC/ECNI-MS mass 
spectra for this bromo  phenol compound. We 
also used the NIST 2005 MS library (National 
Institute of Standards and Technology; 
Gaithersburg, MD, USA) to compare the 
metabolite mass spectra with all spectra avail-
able in the GC/EI-MS database. The NIST 
library confirmed a 98.8% match with the 
methyl derivative of 2,4,6-tribromo  phenol, 
also known as 1,3,5-tribromo-2-methoxy-
benzene. We purchased a commercial standard 
of 2,4,6-tribromo  phenol, which we derivatized 
and compared with peak 1. Although the reten-
tion time of metabolite 1 was 0.5 min later 
than the 2,4,6-tribromo  phenol deriva  tive, the 
molecular ion and ion fragment clusters were 
very similar. The elution time for a compound 
containing a meta-substituted bromine will 
typically be later than the elution time for a 
compound containing an ortho-substituted bro-
mine, as exemplified by the earlier retention 
times of BDE-100 (2,2,4,4´,6-BDE) rela  tive to 
BDE-99 on a DB-5 capillary column (Korytar 
et al. 2005; La Guardia et al. 2006). Thus, it 
is likely that metabolite 1 is 2,4,5-tribromo-
phenol, which would be formed by a simple 
cleavage at the ether linkage. Previous studies 
in which rats were exposed to BDE-99 identi-
fied 2,4,5-tribromo  phenol and its glucuronide 
and sulfate conjugates in rat urine (Chen et al. 
2006). However, an earlier study identified no 
brominated phenols in rats exposed to BDE-99 
(Hakk et al. 2002).
Using 2,4,6-tribromophenol as a stan-
dard, we measured the concentrations of 
2,4,5-tribromo  phenol in all hepatocyte incu-
bations; the mean values are presented in 
Table 2. The mean concentration of tribromo-
phenol was an order of magnitude higher 
in fresh hepatocytes than in cryo  preserved 
hepato  cytes and is likely a result of the 
repeated dosing of the fresh hepatocytes.
We identified two metabolites (metabo-
lites 3 and 4 in Figure 1) as the methyl 
derivative  of  mono-OH-pentabromi-
nated diphenyl ethers (Br5-MeO-BDE and 
5´-MeO-BDE-99). We made a positive 
identifi  cation using a commercially available 
standard for 5´-MeO-BDE-99 and confirmed 
it in both GC/ECNI-MS and GC/EI-MS 
modes. The molecular ion (M+ = m/z 594) 
and primary ion fragment cluster (M-158 = 
m/z 432) for pentabrominated MeO-BDE 
congeners were identified for both metabo-
lites using GC/EI-MS mode. The structure 
of the first eluting Br5-MeO-BDE compound 
could not be positively identified because of 
a lack of standards for all pentabrominated 
MeO-BDEs. However, we can exclude the 
following compounds for which we have 
standards: 2,2´,4,4´,6-pentabromo-5´-meth-
oxy  diphenyl ether (5´-MeO-BDE-100), 
2,2´,4,5,5´-pentabromo-4´-methoxydiphenyl 
ether (4´-MeO-BDE-101), and 2,2´,4,5´,6- 
penta  bromo-4´-methoxydiphenyl ether 
(4´-MeO-BDE-103). Given that laboratory 
exposure studies using polychlorinated biphe-
nyls and PBDEs have typically found oxida-
tive metabolism primarily in the meta or para 
positions (Athanasiadou et al. 2008; Letcher 
et al. 2001; Malmberg et al. 2005; Qiu et al. 
2007), it is possible that metabolite 3 is 
2,2´,4,4´,5-pentabromo-3-methoxy  diphenyl 
ether (3-MeO-BDE-99). Mean concentrations 
of the two pentabrominated MeO-BDE con-
geners are presented in Table 2, and were two 
to three times higher than the concentration of 
2,4,5-tribromophenol. The fresh hepatocytes 
also contained higher concentrations of the 
OH metabolites relative to the cryopreserved 
hepatocytes; this is likely due to the repeated 
dosing of the fresh hepato  cytes. We also found 
5´-OH-BDE-99 at higher concentrations than 
the first eluting pentahydroxy-BDE metabo-
lite in the fresh hepatocytes, whereas in the 
cryopreserved hepatocytes 5´-OH-BDE-99 
Figure 1. GC/ECNI-MS chromatogram (m/z 79 and 81) of the derivatized phenolic fraction isolated from 
fresh hepatocytes incubated with 10 µM BDE-99, identifying the four metabolites 1–4.
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was equivalent or lower in concentration. The 
reasons for this are unclear at this time.
The structure of metabolite 2 has not been 
identified. However, because of the molecu-
lar ion clusters observed in GC/ECNI-MS 
full scan, this metabolite likely contains four 
bromine atoms. Sensitivity was not sufficient 
to allow an analysis by full-scan GC/EI-MS 
needed for determining the molecular mass. 
Previous exposure studies with rats and 
mice have identified oxidative debrominated 
metabolites (e.g., OH-tetrabromo-BDEs) 
after exposure to BDE-99 in vivo (Chen et al. 
2006; Hakk et al. 2002; Qiu et al. 2007). 
Therefore, it is possible that metabolite 2 is a 
tetra-OH-BDE.
mRNA expression. To investigate the 
potential involvement of several metaboliz-
ing enzymes, we investigated the mRNA 
expression of genes encoding these enzymes. 
Because our previous in vitro experiments 
with fish liver tissue found significant reduc-
tive debromination of BDEs by an unknown 
pathway (Benedict et al. 2007; Stapleton et al. 
2006), we decided to examine the regulation 
of several enzymes that are involved in reduc-
tive pathways (e.g., DIs, GSTs, and CYPs): 
CYP1A2, DI1, DI2, GSTM1, and GSTP1. 
We investigated CYP1A2 rather than CYP1A1 
because previous experiments have found no 
up-regulation of CYP1A1 genes in humans; 
however, data from Barber et al. (2006) sug-
gested that lower concentrations of BDE-99 
may result in the up-regulation of CYP1A2 in 
human MCF-7 breast cancer cells. A 2.5-µM 
solution of rifampicin was used as a positive 
control because this compound is a significant 
up-regulator of CYP3A4 (Nishimura et al. 
2007).
Figure 3 shows the absolute transcript 
number of each target gene for cells exposed 
to BDE-99 and BDE-209 relative to control 
cells. Statistical analysis shows that CYP1A2, 
CYP3A4, DI1, and GSTM1 were signifi-
cantly (p < 0.05) up-regulated after exposure 
to both BDE-99 and BDE-209; however, 
the up-regulation was minor compared with 
the up-regulation of CYP3A4 from rifam-
picin (positive control). The up-regulation 
of CYP1A2, CYP3A4, DI1, and GSTM1 in 
BDE-99–exposed hepatocytes was 2.1-, 2.2-, 
1.6-, and 1.6-fold, respectively, and was com-
parable with the up-regulation observed in 
BDE-209–exposed hepatocytes. There was 
no significant effect on either GSTP1 or 
DI2 (data not shown) with either BDE-99 
or BDE-209. The up-regulation of the CYP 
genes and the formation of several oxidative 
metabolites of BDE-99 support a role for 
CYP-mediated metabolism.
DIs are membrane-bound enzymes that 
catalyze the deiodination of thyroid hormone, 
and three subtypes of DI (DIs 1–3) have been 
reported (Kohrle 1999). After dietary expo-
sure to PBDEs, circulating levels of the thyroid 
hormone thyroxine (T4) have been reduced in 
mice (Hallgren et al. 2001), rats (Hallgren et al. 
2001; Zhou et al. 2001, 2002), birds (Fernie 
et al. 2005), and fish (Tomy et al. 2004). One 
possible explanation for these observations is 
that PBDEs induce up-regulation of DI1 and/or 
DI2, thereby increasing deiodination of T4 and 
reducing circulating T4. However, our results 
demon  strate that expression of DI1 (Figure 3) 
is minimally affected after exposure to PBDEs 
and that DI2 was not detected, as we expected 
because of reports that human liver tissues do 
not express DI2 activity (Hulbert 2000; Kohrle 
1999). Another likely explanation is that the 
formation of the OH metabolites was responsi-
ble for the up-regulation of these genes because 
the addition of the OH group increases the 
structural similarities between PBDEs and T4. 
In fact, microsomal conversion of BDE-99 has 
been shown to lead to increased competition 
with T4 for binding to the transporter transthy-
retin, suggesting that PBDE hydroxylation leads 
to increased structural similarities and competi-
tion with T4 (Meerts et al. 2000). Thus, these 
data demonstrate that metabolism of BDE-99 
may involve multiple pathways and that cyto-
chrome P450, as a mono  oxygenase, likely par-
ticipates in the metabolism of BDE-99.
Conclusion
This study demonstrates that BDE-99, and 
perhaps other BDE congeners, is metabolized 
by human liver cells, primarily through oxi-
dative pathways. These observations are very 
similar to results found in previous rodent 
exposure studies. This is particularly simi-
lar to a study by Chen et al. (2006), which 
found 2,4,5-tribromophenol, one mono-
tetra-OH-BDE, and two mono-OH-BDE-99 
metabolites in the feces of rats exposed to 
BDE-99 in vivo. In contrast, our results dif-
fer significantly from metabolism studies on 
fish liver cells, which found that metabolism 
occurred primarily through reductive path-
ways (Benedict et al. 2007; Stapleton et al. 
2004, 2006). It may be the absence of DI2 in 
human liver cells and the high activity of this 
enzyme in fish liver tissue (Eales et al. 1999; 
Orozco et al. 1997) that is responsible for 
this difference. Further studies are warranted 
to determine whether human DI2 enzyme, 
found primarily in brain tissues, can reduc-
tively debrominate PBDEs, because several 
studies have found reductively debrominated 
metabolites of BDE-209 in laboratory-exposed 
rats (Huwe and Smith 2007), lactating cows 
(Kierkegaard et al. 2007), and occupation-
ally exposed workers (Thuresson et al. 2005, 
2006). Regardless, the oxidative metabolites 
observed in this study should be measured in 
human serum in the future because studies 
have demonstrated increased toxicity from 
these oxidative metabolites.
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